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Summary
CD69, a surface dimer so far considered an early activation antigen restricted to lymphocytes,
was found constitutively expressed on humanplatelets. Biochemical analysis revealed that platelet
CD69 appears on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a broad 55-65-
kD band, in which three 55-, 60-, and 65-kD components were detectable when nonreduced,
and as two 28- and 32-kD bands when reduced, corresponding to the two disulfide-linked chains
of the dimer. It therefore closely resembles lymphoid CD69, although the resolution of the three
bands under nonreducing conditions is not usually seen in lymphoid cells. Moreover, as CD69
expressed on activated lymphocytes and CD3b°ght thymocytes, both chains are constitutively
phosphorylated.
CD69 stimulation by anti-Leu-23 monoclonal antibodies induced platelet aggregation in a
dose-dependent fashion. This effect was associated with Ca2 + influx and platelet degranulation,
as revealed by adenosine triphosphate release. In addition, CD69 stimulation in platelets induced
production of thromboxane B2 and PGE2, suggesting activation of arachidonic acid metabolism
by cycloxygenase. As observed for CD69-mediated T cell activation, platelet activation through
CD69 requires molecular crosslinking. Theseresults suggest that CD69 may function as an activating
molecule on platelets, as on lymphocytes, and point toward a more general role of this surface
dimer in signal transduction.
C
D69 (formerly called EA1, MLR-3, Leu-23, and AIM)
is a disulfide-linked surface homodimer composed by
two chains of 28 and 32 kD (1, 2). Both chains have the same
24-kD proteic backbone, but they appear to be differently
glycosylated by Winked sugars (3, 4). The dimer may be
formed by the random association of the 28-kD chain with
another 28-kD chain or with the 32-kD chain, as well as
by the association of the 32-kD chain with another 32-kD
chain. The three molecular forms appear to coexist on the
surface of the same cell. Both chains are constitutively phos-
phorylated (1, 3, 5) and are likely to be integral membrane
proteins.
CD69 was initially detected on the surface ofactivated lym-
phocytes. Resting T lymphocytes in fact do not express CD69,
but its expression may be rapidly induced by triggering of
their TCR/CD3 complex (1, 2, 6) . Similarly, CD69 is in-
duced on the surface of NK cellsby interaction of IL-2 with
the p75 IL-2R (3, 7). CD69 induction is extremely rapid,
being detectable within 2 h from the stimulation, yet requiring
new RNA and protein synthesis (1, 6). Its expression on T
cells stimulated through the TCR/CD3 complex quantita-
tively correlates with the extent of TCR/CD3 crosslinking
(6), and is strictly dependent on the activation of protein ki-
nase C (PKC)' and on the maintainance in time of elevated
intracellular [Ca2 +] levels (6).
In vivo, CD69 was found constitutively expressed and phos-
phorylated on CD3bt'ght thymocytes, with a linear relation-
ship between levels of CD69 and levels of expression of sur-
face CD3 (5). These include all single-positive cells, and 10%
of double-positive CD3bright cells. A small number of cir-
culating large T and NK cells have also been found to be
CD69+, possibly as a result of in vivo activation (3).
A physiologic ligand for CD69 has not yet been identified,
but experimental evidence indicates that the molecule is capable
of signal transduction (8). Anti-CD69 mAbs, in fact, induce
Ca2+ influx in CD69+ T cells and, when PKC is simul-
taneously and independently activated, lymphokine gene ex-
pression and secretion, ultimately leading to cell prolifera-
'Abbreviations used in this paper: DG, diacylglycerol; ECM, extracellular
matrix; GaM, goat anti-mouse; PFP, plasma-free platelet; PIP2, phos-
phatidyl inositol diphosphate; PKC, protein kinase C; PLC, phospho-
lipase; PRP, platelet-rich plasma; TXB2, thromboxane B2; VLA, very
late activation antigen.
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appears to be sensitive to cyclosporin A (10) and dependent
on membrane expression of CD3 (11, 12). CD69+ B cells
also areinducedto proliferate by CD69 stimulation and simul-
taneous PKC activation (11).
To investigate the possible general relevance of CD69 as
a signal-transducing molecule, we analyzed the expression
of CD69 in nonlymphoid cells. We found that CD69 is ex-
pressed on resting platelets. The biochemical characteristics
ofplatelet CD69 closelyresemble thoseoflymphoid CD69.
Moreover, themolecule is able to transmit asignal that results
in platelet activation and aggregation. These results indicate
a more generalized role for CD69 in cellular signaling and
may help define possible ligand candidates.
Materials and Methods
Cells.
￿
Platelet-richplasmas (PRPs) were obtained from healthy
adult donors, 30-60yr old. Venous blood samples were collected
(9:1 [vol/vol]) with ACDbuffer (2.5% Na citrate, 1.5%citric acid,
2% dextrose)andcentrifuged at 150g for 15 min.Forplasma-free
platelet (PFP)preparation, PRPs were washed twiceandresuspended
in Hepesbuffer (10mM Hepes buffer, pH 7.4,containing 119 mM
NaCl, 5 mM KC1, 2 MM MgC12, 25 mM NaHC03, 0.1 U/ml
Hirudin [Sigma Chemical Co., St. Louis, MO], and 0.5 mg/ml
Apyrase [Sigma Chemical Co.]).
Jurkat cellswere cultured in RPMI 1640 (Whittaker M.A. Bio-
products, Walkersville, MD), supplemented with 1mM glutamine,
antibiotics, and 10% FCS (Biological Industries, Kibbutz Beth
Haemek, Israel) . To maximally induce CD69, Jurkat cells were
grownovernightin thepresence of 10 ng/mlPMA(Sigma Chem-
ical Co.).
mAbs.
￿
Anti-Leu-23 (IgGI, anti-CD69), anti-Leu-3a (IgG1, anti-
CD4),anti-Leu-2a (IgGI, anti-CD8), andcontrol mouseIgGl were
kindly provided by Dr.L.L. Lanier (Becton Dickinson&Co., Moun-
tain View,CA). Anti-EA-1 (IgGl, anti-CD69) was a gift from Dr.
S. M. Fu (OklahomaMedicalResearch Foundation, Oklahoma City,
OK). Anti-gp IIb-IIIa (IgG1) was purchased from Pel-Freez Bio-
logicals, Rogers, AR). Anti-Leu-23 mAb was coupled to Pandex
(IDC, Portland, OR) beads as previously described(6). F(ab') frag-
ments of anti-Leu-23 mAbwere prepared by pepsin digestion and
HPLC fractionation, followed by mild reduction and alkylation,
accordingto Parham (13). Goat-anti-mouse (GaM) Ig wasobtained
from Tago Inc. (Burlingame, CA).
Immunofluorescence and Cytofluorimetric Analysis. PFPs were
resuspended in 100 FAlof PBS, and optimalamounts ofmAbs were
added. After 20 min on ice, they were washed twice with cold
PBS, andan optimalamount of FITC anti-mouse IgGwas added.
After 20 min on ice, they were washed once, resuspended in cold
PBS, and immediately analyzed. Analysis was performed with a
FACScan cytofluorimeter (Becton Dickinson & Co.). 104 events/
sample were collected, and data were processedby Consort 30 soft-
ware and presented as single fluorescence histograms on a four-
decades log scale.
Labeling Immunoprecipitation, andSDS-PAGE Analysis.
￿
For "5I
labeling, 109 PFPs and2 x 106Jurkat cells were washed twice and
resuspended in D-PBS without Cat' and Mgt* containing 10-6
MKI. For cell suspension, 200 jtl of a 50-pg/ml lactoperoxidase
(Sigma Chemical Co.) solution and 10,ul of a 20-IU/ml glucose
oxidase (Sigma Chemical Co.) in D-PBS/10-6 MKI solution were
added. 2 mCi I'll (Amersham International, Amersham, UK) was
added to 0.5 ml of 10 mM glucose in the D-PBS/10-6 M KI so-
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lution andthen mixedwith theenzyme-cell suspension. Cells were
kept at room temperature for20 minwith occasional mixing. Cells
were then washed threetimeswith cold PBS/0.1% azideandlysed
in 0.5 ml of 0.5% NP-40 lysis buffer (0.05 M Tris-HCI, pH 8,
0.15 M NaCl, 1 mM EDTA, 0.02% NaN3, 20 KIU/ml aprotinin)
for 30 minon ice. Supernatants collectedafter centrifugation were
immunoprecipitated.
For 32PO4 labeling, 109 platelets were washed three times in
Hepes buffer and resuspended in 2 ml of Hepes buffer. 2 mCi
"P04 was then delivered to the cell suspension, and cells were in-
cubated at 37°C for3 h. Cellswere then washed threetimeswith
cold PBS/0.1% azide containing 0.1 mM Na3V04, 0.4 mM
EDTA, 10 mM Na4P20,, 10 mM NaF, and lysed in 0.4 ml of
0.5% NP-40 1ysis buffer for 30 min on ice. Supernatants collected
after centrifugation were immunoprecipitated.
Cell lysates were precleared three times with formalin-fixed Staph-
ylococcus aureus (Pansorbin; Calbiochem-Behring Corp., La Jolla,
CA)coated with rabbit anti-mouse (RaM) Ig (Dako Corp., Den-
mark). Immunoprecipitation was performed using anti-Leu-23
mAbs boundto RaMS. aureus. After seven washes in lysis buffer,
immunoprecipitates were resuspended in 50 pl sample buffer, boiled
for 5 min, and run on a 10% SDS-PAGE. Gels were fixed for 30
min in a 50% methanol, 7.5 pH acetic acid solution. saP04 gels
were also treated o.n . with a 10% TCA, 50 mM NaH2PO4 solu-
tion. Finally, gels were dried and autoradiographed.
Platelet FunctionalStudies.
￿
Afterthelast wash with Hepesbuffer,
platelets were resuspended at 2 x 108/ml in Hepesbuffer without
Hirudin and Apyrase, supplemented with 10 mM glucose, 0.2%
BSA, 1 mM CaC12, and 100 ttg/ml human fibrinogen . Aggrego-
metric assays were performed with a dual sample aggregometer
(840;Elvi,Milano, Italy) in polypropylenetubes, at 37°C, and were
stirredat 1,000rpmafteradding various amountsofmAbs to PFPs,
in a total volume of 0.25 ml. ATP release was measured with a
luminometer (1241, LKB Wallac, Turku, Finland). A 50-ulwork
solution (80 pg/ml luciferin, 8,800 U/ml d-luciferase) was mixed
with 450'41 PFPs before adding mAbs. Formeasurement ofreleased
thromboxane A2 (measured as TXB2) and PGE2, platelets were
stimulated with mAbs in a total volume of 0.25 ml in polypro-
pylene tubes, at 37°C, and were stirred at 1,000 rpm for 10 min,
then 14 p,Mindomethacin wasaddedto stop cycloxygenase activity.
Supernatants were collected, and TXB2 and PGE2 were measured
by RIA (NEN, Dreieich, FRG).
Intracellular(Ca2*]Measurement.
￿
PRPs were incubated for 1 h
with 4PM Fura-2 (Calbiochem-Behring Corp.), then washed twice
to obtain PFP (see above) and resuspended in Hepes buffer sup-
plemented with 1 mM CaC12. Aliquots of 1.5 ml were stimulated
with mAbs, and fluorescence variations were monitored with a
spectrofluorimeter (SFM25; Kontron, Zurich, Switzerland), setto
340 nm excitation and 510 nm emission. Fura-2 signals were
calibrated according to Pollock et al. (14). Cell iysis by 50 AM
digitonin allowed to determine Fm., while addition of 10 mM
EGTA in a 20-mM Tris base allowed to set F,;.
Results
PlateletsExpress CD69.
￿
To assess theexpression of CD69
on human platelets, PFPs were adjusted to 108/ml. Aliquots
were then stained with the appropriate amounts ofanti-Leu-
23 and anti-EA1 (which recognize different epitopes of the
CD69 molecule), anti-Leu-3a, anti-Leu-2a, andmouse IgG1
as negative controls, and anti-gp IIb-IIIa as positive control,
followed by second-step FITC-conjugated goat anti-mouse
IgG. Samples were analyzed by a FACScan cytofluorimeter.d a
E
c
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Figure 1 .
￿
CD69 expression on platelets. Aliquots of PFPs were
stained with anti-Leu-3a (A), anti-Leu-23 (B), anti-EA-1 (C), and
anti-gp IIb-IIIa (D) mAbs, then with FITC-conjugated anti-mouse
IgG, and analyzed by FACS. Staining with FITC-conjugated
anti-mouse IgG only is superimposed in each panel (shaded areas) .
Fig. 1 shows that CD69 was clearly detectable by both anti-
Leu-23 mAb (B) and anti-EA-1 mAb (C), although its ex-
pression was -20-30-fold lower than the gp IIb-111a expres-
sion (D) . Control anti-Leu-3a mAb (as well as anti-Leu-2a
and control mouse IgG1, not shown) did not stain platelets
(Fig . 1 A) . CD69 was detected on all (8/8) donors tested .
Failure to reveal CD69 on platelets by previous cytofluori-
metric analyses (1) may be attributed to insufficient instru-
ment sensitivity in detecting relatively low amounts of an-
tigen . Attempts to increase CD69 expression by PMA (10
ng/ml) or thrombin (0.5 U/ml) stimulation of PFPs
resuspended in Hepes buffer supplemented with 1 mM
CaC12 were unsuccessful (data not shown) .
Platelet CD69 is Biochemically Similar to Lymphoid CD69.
CD69 was immunoprecipitated from PFPs radiolabeled with
111 1, using the anti-Leu-23 mAb, and run on a 10% SDS-
PAGE. As a control, CD69 was also immunoprecipitated from
Figure 2.
￿
Biochemical analysis of platelet CD69 . PFPs (lanes A, B,
E, F) and Jurkat cells (lanes C, D, G, H) were labeled with 12%
then cell lysates were treated with S. aureus/RaM-bound control
IgGI (lanes A, C, E, G) or anti-Leu-23 mAbs (lanes B, D, F, H) .
Immunoprecipitates were run on 10% SDS-PAGE under nonreducing
(lanes A-D) and reducing (lanes E-H) conditions .
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Figure 3 .
￿
Phosphorylation of
platelet CD69 . PFPs were washed
extensively in Hepes buffer before
loading with 32POa . Cell lysates
were treated with S. aureus/
%M-bound control IgGI (lane A)
or anti-Leu-23 mAbs (lane B) . Im-
munoprecipitates were run on 10%
SDS-PAGE under reducing con-
ditions .
the Jurkat tumor T cell line, after overnight PMA stimula-
tion and 1251 radiolabeling. Fig . 2 shows that, under non-
reducing conditions, platelet CD69 is a diffuse 55-65-kD band,
in which, however, three discrete components of -55, -60
and -65 kD, corresponding to the three dimeric combina-
tions of 28+28, 28+32, and32+32W, were detectable (Fig.
2 lane B) . Under reducing conditions, two bands of 28 and
32 kD were visible (lane F) . CD69 from platelets migrated
in essentially the same positions as CD69 from Jurkat (lanes
D and H), suggesting close similarity between the two .
Moreover, since both chains ofCD69 have invariably been
shown to be phosphorylated on activated T cells, as well as
on activated NK cells and thymocytes, we analyzed the phos-
phorylation status of platelet CD69 . Resting platelets were
therefore loaded with 32POa, CD69 immunoprecipitated
with the anti-Leu-23 mAb, and run on 10% SDS-PAGE . Fig.
3 shows that both the 28- and the 32-kD chains are phos-
phorylated (lane B) .
Anti-CD69 mAbs Induce Platelet Aggregation andDegranu-
lation. The functional implications for CD69 expression on
platelets were therefore investigated . To evaluate a possible
role for CD69 in platelet activation, we first analyzed the
ability ofanti-CD69mAbs to induce aggregation. Anti-CD69
mAbs induced platelet aggregation after a lag phase that was
inversely dose dependent . In the experiment shown in Fig.
4, aggregation was induced after 1.5, 2.5, and 4 min by 16
(A), 8 (B), and 4 (C) Wg/ml, respectively, ofanti-Leu-23 mAb.
By contrast, 16 wg/ml of anti-gp IIb-IIIamAb (D) was un-
able to induce aggregation.
Degranulation, usually revealed by ATP release, often ac-
companies and amplifies platelet activation. To assess whether
CD69 triggering resulted in platelet degranulation, PFPs were
stimulated with 12 ug/ml of anti-Leu-23 mAb, and ATP
released in the supernatant was measured . As shown in Fig.
5, CD69 stimulation by anti-Leu-23 mAb induced significant
ATP release, while control anti-gp IIb-IIIamAb had no effect.
ATP release and platelet aggregation by soluble anti-CD69
mAb were observed in 50% of the donors tested (6/12), al-
though all donors expressed comparable amounts of CD69
on platelets. Platelets from donors that did not respond to
soluble anti-CD69, however, were induced to release ATP
and aggregate by maximizingCD69 crosslinking with anti-
Leu-23-coupled Pandex beads (not shown) .
Requirementfor Crosslinking.
￿
CD69-mediated T cell acti-Figure 4 .
￿
Induction of platelet aggregation by anti-CD69 mAb.
Anti-Leu-23 mAb, at a final concentration of 16 (A), 8 (B), and 4
(C) Kg/ml, and anti gp Ilb-1112 mAb at 16 Eaglml (D) was added to
PFP aliquots at time 0. Changes in light transmission, due to cell
aggregation, were continuously recorded by a dual sample
aggregometer.
vation requires extensive crosslinking ofCD69 molecules in
most donors (9, 10) . To further analyze the requirement for
crosslinking in CD69-mediated platelet activation, experi-
ments were performed comparing monovalent F(ab') frag-
ments to intact IgG, in donors that responded to the soluble
mAb. Fig. 6 shows that anti-Leu-23 F(ab') fragments were
unable to induce ATP release (and platelet aggregation; not
shown) . When a second-step GaM was added, however, F(ab')
fragments induced ATP release in amounts comparable with
those induced by the intactmAb. Taken together, these results
indicate that optimal molecular crosslinking is crucial also
for CD69-mediated platelet activation .
Anti-CD69 mAbs Induce Cal' Influx .
￿
Since CD69-medi-
ated signaling in lymphocytes includes extracellular Cal +
influx, we tested whether anti-CD69 mAbs were able to
generate an increase in intracellular [Ca2 +] in platelets (Fig.
7) . PFP stimulation with 0.5 U/ml thrombin (Fig. 7 A) or
with 12 ug/ml of anti-Leu-23 (Fig. 7 B) resulted in intracel-
lular [Ca2+] elevations that persisted for several minutes.
Anti-gp IIb-111a (C) or anti-Leu-3a (not shown)mAbs failed
to alter intracellular [Ca 2 +] levels. Prior addition of 2mM
EGTA (D) completely prevented the observed intracellular
[Ca2+] elevation, suggesting that anti-CD69 stimulation
was inducing extracellular Ca2+ influx.
CD69 Stimulation Activates the Cycloxygenase Pathway .
￿
Ar-
achidonic acid metabolism by cycloxygenase is a major bio-
chemical pathway leading to the formation of potent medi-
aoo
2 4 6
min
Figure 5 .
￿
Release of ATP from
platelets by CD69 stimulation . Ali-
quots of PFPs were stimulated with
12 Kg/ml anti-Leu-23 mAb (A), 12
gg/ml anti-gp IIb-IIIa (O), or left
unstimulated (A), and ATP release
in the supernatant was measured by
a luminometer. Amounts of released
ATP are plotted vs. time elapsed
from the stimulation (tune 0) .
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Figure 6.
￿
Requirement for CD69
crosslinking . Aliquots of PFPs were
stimulated with 12 Ag/ml of intact
anti-I.eu-23 IgG (0), 12 Ag/ml of
anti-Leu-23 F(ab') (A), 12 Ag/ml of
GaM (O), or 12 Ag/ml of anti-Leu-
23 F(ab'), followed after 2 min by
12 Ag/ml ofGaM (" ) . Released
ATP is plotted vs . time elapsed from
min
￿
the stimulation (time 0) .
ators involved in the amplification and regulation of platelet
responses (15) . Cycloxygenase activation in platelets results
in endoperoxides (PGG2, PGH2) formation, with subse-
quent PGE2 generation by isomerization . TXA2 is then pro-
duced by TXA2-synthetase from PGH2, and is rapidly con-
verted to TXB2 . We measured PGE2 and TXB2 in the PFP
supernatant after CD69 stimulation with 12Ag/ml anti-Leu-
23 mAbs (Fig. 8). Both PGE2 (Fig. 8 A) and TXB2 (Fig.
8 B) were released in the supernatant of PFPs treated with
the anti-Leu-23 mAb, while anti-gp IIb-11h mAb had no
effect, indicating activation of cycloxygenase and TXA2-
synthetase upon CD69 stimulation .
Discussion
The data presented here indicate that human platelets con-
stitutively express CD69, a molecule so far considered an early
activation antigen restricted to lymphoid cells. Moreover, we
provide evidence that platelet CD69, similarly to lymphoid
CD69, may be involved in signal transduction, since CD69
crosslinking by mAbs generates Cal + influx with conse-
quent platelet activation and aggregation.
CD69 is a disulfide-linked homodimer that has been de-
U
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Figure 7 .
￿
Induction of [Ca2+1 influx in platelets by anti-CD69
mAb. PRPs were loaded with Fura-2, then thrombin at 0 .5 U/ml (A),
anti-I--u-23 mAb at 12 Ag/ml in the absence (B) or in the presence
of 2 mM EGTA (D), and anti-gp IIb-111a at 12 Wg/ml (C) were
added to PFP aliquots at time 0. Changes in fluorescence emission
were continuously recorded by a spectrofluorimeter. [Ca2+1 was mea-
sured by 50 AM digitonin (Fm-) and 10 mM EGTA (F io ) cali-
bration .o s to to m
rig/10 9 O+"
Figure 8.
￿
Production of PGE2
and TXB2 upon CD69 stimula-
tion. Aliquots of PFPs were left
untreated or stimulated with 12
Pg/ml of anti-Leu-23 or anti-gp
IIb-1IIa mAbs. PGE2 (A) and
TXB2 (B) released in the super-
ng 1 to s
￿
natant were measured by RIA .
scribed as an antigen induced very early during lymphoid
activation (1-3, 5, 8). Its expression, which requires new RNA
and protein synthesis, is strictly dependent on PKC activa-
tion (4, 6, 16) . In vivo, CD69 is found on thymocytes ex-
pressing high levels ofCD3, possibly as a result ofintrathymic
TCR/CD3 engagement (5) . CD69 on T lymphocytes ap-
pears to be functionally linked to a Cal+ channel. Anti-
CD69 mAbs, in fact, induce Cat+ influx when properly
crosslinked on the surface of CD69+ T cells (9, 10) . This
influx is prolonged in time and contributes, when PKC is
simultaneously activated, to lymphokine gene activation .
CD69-induced IIr2 and IFN--y gene expression are in fact
completely blocked by EGTA (10) . On the other hand, sig-
naling through CD69 in T cells is not likely to result in an
effective activation of PKC, from phosphatidyl inositol di-
phosphate (PIP2) hydrolysis and diacylglycerol (DG) forma-
tion, since C1369-induced gene activation always requires in-
dependent PKC stimulation (10, 16) .
The presence ofa protein that antigenically, biochemically,
and functionally resembles CD69 on resting platelets is in-
triguing. Other molecules induced or upregulated on acti-
vated T lymphocytes have been shown to be constitutively
expressed on platelets . These include members of the very
late activation antigen (VLA) group of proteins of the inte-
grin family, which function as extracellular matrix (ECM)
receptors. Collagen receptor (ECMR II) platelet gp Ia-IIa
(17) and fibronectin receptor (ECMR IV) platelet gp Ic-IIa
(18) are identical toVLA-2 andVLA5 respectively, expressed
on long-term activatedT cells (19) . Moreover, platelet laminin
receptor VLA6 (20) is upregulated on activated T cells (A .
Santoni, unpublished results) . VLA2, -5, and -6 may there-
fore functionon platelets as activation-independent receptors
for ECM proteins, and possibly for ECM-mediated platelet
activationand aggregation, while on activated lymphocytes,
they are supposed to be involved in mechanisms of endothelial
adhesion, extravasation, and tissue penetration (19) . VLAs
on lymphocytes are acquired or upregulated several days after
the stimulation, and persist on the cell surface, possibly for
the entire cell life. The upregulation of CD29 (platelet gp
IIa), the /3 t chain of the integrin family, shared by all VLAs,
has been in fact proposed as a phenotypic marker formemory
T cells in vivo (21) .
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PTA1, a 67-kD glycoprotein ofunknown function, is also
expressed by activated T cells and resting platelets. mAbs
against PTA1 induce platelet activation and aggregation (22),
but not T cell activation (23) . On T cells, PTA1 expression
is slowly upregulated during activation and still maintained
several days after the stimulation (23) .
By contrast, CD69 is a transiently expressed activation an-
tigen . On T cells, CD69 is induced within 2 h after the stim-
ulation of the TCR/CD3 complex . Experiments designed
to evaluate the membrane turnover of the protein on T cells
indicated that once maximally induced in vitro on the cell
surface (within 18-24 h), CD69 has a t1/2 of-24 h, if the
inducing stimulus is removed (6) . Cells that express CD69
without in vitro stimulation, like CD3brigbt thymocytes and
a few circulating lymphocytes, are likely to have acquired their
expression in vivo as a result of a recent stimulation, and in
fact, progressively lose CD69 expression when cultured in
vitro without stimulation (R. Testi, unpublished results) .
CD69 is therefore needed for a short period of time during
the stimulation . It has been suggested that CD69 might be
functionally associated with an IIr1R (2) . However, the present
data would not encourage us to generalize this hypothesis,
since no effect of IIr1 or 1IAR on platelets has been reported .
mAbs directed against other structures present on resting
platelets may directly trigger platelet activation and aggrega-
tion . CD9 (gp 24), whose ligand is unknown, can induce
DG formation, degranulation, TXA2 production, and ag-
gregation, whenbound by anti-CD9 mAbs (24-26) . mAbs
against CD36 (platelet gp IV), an activation-independent
thrombospondin receptor, also induce PKC-dependent platelet
aggregation (27) .
CD69 crosslinking in platelets generates [Ca2 +] influx
and a number of activating events, which include degranula-
tion, arachidonate metabolism by cycloxygenase with forma-
tion and release of PGE2 and TXB2, and finally, platelet
aggregation .
A significant increase of intracellular [Ca2+] is generally
considered sufficient to trigger most of the activation events
that lead to platelet adhesion and aggregation (15) . Intracel-
lular [Ca2 +] levels in platelets are primarily controlled by
inositol 1-4-5 triphosphate (release from internal stores) (28,
29), and possibly also by inositol 1-3-4-5 tetrakiphosphate
(extracellular Ca2+ influx) (30), mostly derived from PIP2
metabolism . In fact, strong platelet agonists (thrombin, col-
lagen, TXA2, platelet-activating factor) and some weak
agonists (vasopressin, epinephrine) stimulate receptors coupled
to specific Gp proteins (31, 32) that activate phospholipase
(PLC) and PIP2 metabolism (33, 34) . However, PLC-inde-
pendent receptor-operated Ca2+ channels may be opened by
ADP (35), and possibly also by TXA2 (36) .
Although is not clear at the moment whether CD69-
induced Ca2+ influx is PLC independent, it may be directly
responsible for a variety of [Ca2+]-dependent events that
contribute to platelet activation and aggregation .
[Cal+]-dependent proteases are responsible for cleavage of
actin-binding proteins and of p235, involved in cytoskeleton
reorganization during platelet aggregation (37) . [Ca2 +]/
calmodulin-dependent kinases may be directly activated byelevated intracellular [Ca' +] and control the phosphorylation
of the 20-kD myosin L chain, necessary for shape change (38)
and possibly contraction and secretion. Finally, PLA2 is ac-
tivated in the presence of elevated intracellular [Ca2+] (39),
allowing arachidonic acid release from membrane phos-
phatidylcholine and phosphatidylethanolamine, and subse-
quent activation of cycloxygenase with PG endoperoxides
PGG2/PGH2 and PGE2 synthesis and TXA2 formation.
The results presented here strongly suggest that CD69 cross-
linking results in the activation ofthe cycloxygenase pathway,
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